Podcasts about Boston Scientific

The range of symptoms and affected body systems in Parkinson's disease is extensive. One area that is less frequently discussed is the vestibular system—the inner ear structure directly connected to the brain, responsible for balance and spatial orientation. When this system malfunctions, individuals may experience dizziness, balance problems and an increased risk of falls, highlighting its importance in your overall health. With aging, the inner ear naturally becomes less robust. Although current research has not yet identified a definitive cause for the higher incidence of vestibular dysfunction in people with Parkinson's disease, effective interventions are available. In this episode, Christopher Taylor, Occupational Therapist at Mayo Clinic, will provide insights into the diagnosis and treatment options—namely vestibular therapy—that can assist with symptoms such as dizziness, gait disturbances, freezing, and postural instability. This discussion aims to enhance our understanding of the crucial role played by the inner ear and its connections. Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches  https://vestibular.org/

Melissa E. Middeldorp, MPH, PhD is joined by Thomas F. Deering, BS, MBA, MD, FHRS, CCDS, and T. Jared Bunch, MD, FHRS to discuss a 31-item questionnaire was developed and distributed among healthcare professionals via the EHRA network and social media between 23 September and 21 October 2024. https://www.hrsonline.org/education/TheLead https://academic.oup.com/europace/article/27/4/euaf075/8099191?login=false Host Disclosure(s): M. Middeldorp: Nothing to disclose. Contributor Disclosure(s):   T. Deering: Honoraria/Speaking/Consulting: Sanofi, Pacemate, Pfizer, Inc., Omny Health, Preventice Research: Abbott, Boston Scientific, Medtronic, Biotronik, Biosense Webster, Inc.,  Stock Options - Privately Held: HeartBeam Officer, Trustee, Director, Committee Chair: Board Membership T. Bunch: Honoraria/Speaking/Consulting: Pfizer, Inc. Heart Rhythm Society

What does it really take to lead with empathy in today's fast-paced world? Today we invited Angie Morgan, a New York Times bestselling author and Marine Corps veteran. She reveals how blending mission-driven leadership with genuine care for your people creates unstoppable teams.   In this insightful conversation, Angie dives deep into the evolving world of leadership. From her time in the Marine Corps to leading multinational companies, Angie teaches us how empathy, clarity, and courage are the foundation for effective leadership. Learn how to strike the balance between caring for your team and driving results without compromising your mission. Whether you're a leader or aspiring to be one, this episode is packed with real-world wisdom that will help you rise to your best leadership potential.   Here are highlights:   -Empathy in Leadership: How understanding and connecting with your team's emotions fosters stronger performance and results, without lowering expectations. -Leading from the Front: The Marine Corps philosophy of "Mission First, People Always" and how it can transform your approach to leadership in any business. -The Power of Clarity: Angie explains how getting clear on your vision and purpose is the first step toward leading yourself and others effectively. -Courage to Take Risks: Why embracing calculated risks is essential for leadership growth, and how to overcome the fear of failure. -Authenticity in Leadership: Angie reflects on the importance of leading as your true self and how authenticity breeds trust and respect within your team.   About the guest: Angie Morgan is a respected author, leadership expert, and thought leader, having written three books on leadership: Leading from the Front, Spark, and Bet on You. She's a regular contributor to publications like Harvard Business Review, Fast Company, and Inc. For the past 20 years, Angie has worked with major organizations such as Google, FedEx, and Boston Scientific, helping them develop leadership potential through keynotes, consulting, and coaching. Passionate about empowering others, she shares insights via her blog, social media, podcast, and online courses. When she's not helping others succeed, Angie enjoys spending time with her two boys and training for her next race by the lakeside in Traverse City, Michigan.     Connect with Angie: LinkedIn: https://www.linkedin.com/in/theactualangie/ Website: https://angieconnect.com/   Connect with Allison: Feedspot has named Disruptive CEO Nation as one of the Top 25 CEO Podcasts on the web, and it is ranked the number 6 CEO podcast to listen to in 2025! https://podcasts.feedspot.com/ceo_podcasts/ LinkedIn: https://www.linkedin.com/in/allisonsummerschicago/ Website: https://www.disruptiveceonation.com/    #CEO #leadership #startup #founder #business #businesspodcast  Learn more about your ad choices. Visit megaphone.fm/adchoices

Ee acordo com os dados do Ministério da Saúde de 2023, quase 25% da população têm obesidade. A condição também pode contribuir para o surgimento de uma série de problemas de saúde associados, estigma e preconceito que pessoas com sobrepeso encaram na sociedade e mais.Neste episódio, o dr. Drauzio Varella conversa com o dr. Almino Ramos, cirurgião bariátrico, e o dr. Eduardo Grecco, gastrocirurgião e endoscopista, sobre os tratamentos disponíveis e as novidades no enfrentamento à obesidade. Conteúdo produzido com o apoio da Boston Scientific e seu canal Saber da Saúde. Acesse: Leve a Vida Mais LeveVeja também: O Wegovy é uma opção segura para tratar a obesidade?

Jennifer Kaplan is the founder and CEO of Evolve Public Relations and Marketing, a premier PR agency she established in 2010 to help businesses and professionals authentically tell their stories. With a communications degree from Arizona State University and an entrepreneurial spirit, Jennifer has dedicated her career to elevating brands, building trust, and fostering meaningful connections.Jennifer comes from a family of entrepreneurs, so forging her own path was a no-brainer! As a young professional, she left her steady sales job to take on her first client, boldly launching herself into the rest of her career. In 2005, she co-founded her first PR start-up, PRIME 3, LLC, but later sold her share to branch out and start Evolve! Now, her team works across industries to provide media coverage, influencer engagement, reputation management, and crisis communications.Jennifer's work has garnered widespread acclaim. She's been honored as one of “The Most Influential Women in Arizona Business” by AZ Business Magazine, a “40 Under 40” by Phoenix Business Journal, a “Woman of Achievement” by InBusiness Magazine, and the inaugural Hugh Downs School of Human Communication Alumni of the Year.When Jennifer isn't running her agency, she fills her cup with yoga, cheering on the ASU Sun Devils, and of course, spending time with her family. Connect with Jennifer Kaplan and Evolve PR & Marketing:

What You'll Learn:Why real leaders don't always have the title—or the powerHow Becky's Stoic-inspired Choose the Handle That Holds became a guidebook for life and leadershipThe difference between authentic vulnerability and oversharingA live demo of STOA: a goal-setting tool you'll want to use immediatelyHow to model leadership for your team, your family, and yourself 

In this episode of Medsider Radio, we sat down with Maulik Nanavaty, CEO of Anumana. Anumana, an AI-driven health technology company focused on cardiovascular care, is taking a pragmatic approach to scaling AI in medicine.Maulik is a seasoned healthcare executive with over 30 years of global experience in the medical device industry. He spent 18 years at Boston Scientific, where he led its $1B+ Neuromodulation division and served as President of Boston Scientific Japan. Prior to that, he held leadership positions at Baxter. Known for driving innovation in implantable and artificial intelligence (AI)-powered technologies, Maulik also serves on the board of Rani Therapeutics.In this interview, Maulik shares why building a strong risk-benefit case and designing around real-world clinician needs are key to adoption. With data from over 20 million patients and a focus on transparency, Anumana is reshaping how AI reaches the point of care.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Maulik Nanavaty.

One of the possibilities along the Parkinson's journey is losing the ability to drive safely. This possibility is a scary one. For many, driving equals independence. So, it means more than just the hassle of getting around. It means losing your independence. It can lead to depression and anxiety. However, it is important to be safe on the road while driving a multi-ton vehicle. We must protect ourselves, our family, and others on the road. So, we are talking today with an Occupational Therapist who is so passionate about this topic that she started a business focused on helping people keep their independence if possible. She will take us through the when, why, how of driving while diagnosed with Parkinson's. OTs are the professionals trained to assess patients on activities of daily living which includes testing people on their driving skills. We discuss the testing process and the legal implications. There are many options for people once it is determined there is a driving defiicit. So, don't give up. Ask an Occupational Therapist for suggestions.  Listen in to learn everything about driving with PD. https://drivingtoindependence.com/ https://www.aded.net/? https://www.dbsandme.com/17branches Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

Live from Medtech MVP, Michael Mahoney, chairman and CEO of Boston Scientific Corp, sits down with Medtech Talk podcast host Justin Klein. They discuss Mahoney's communications strategies to align expectations and convey intentions to shareholders, how to delegate and streamline decision making, and advice on doing better as a partner. Mahoney also shares which second order considerations (such as manufacturing) are important to keep in mind, as well as whether he's a “war time” or “peace time” CEO and what challenges the industry needs to address today to create a better tomorrow.   Medtech Talk Links:  Cambridge Healthtech Institute   Medtech Talk  Gilde Healthcare  Boston Scientific Corp: Boston Scientific Corp 

Where do you exercise? Is there a place you can take classes specific for people with Parkinson's? Is it convenient? I know of only a handful of cities where there is a one stop fits all approach to PD wellness. Most are created and managed by someone stepping up and doing the work to make it happen for their community and beyond. I am excited to highlight some of these magical places where people with Parkinson's take classes designed for their needs, provide social support, and community. I am thrilled to bring. you this first magical place. It is in the greater the Austin, TX area and on their YouTube chamnnel. Power For Parkinson's was founded by two women, Dr. Nina Mosier and Susan Stahl. They both had fathers with Parkinson's and saw a need, so they found a way to provide research-based exercises while offering them for FREE. With nine locations, the classes are very accessible. Add in the YouTube channell with available streaming and on demand videos all for free, well that is magical. After listening to my guest today, you are going to want to have a similar opportunity in your area as well. Listen on. https://www.powerforparkinsons.org/ https://www.powerforparkinsons.org/youtubeq https://www.dbsandme.com/17branches Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

D'éirigh le fostaithe Boston Scientific i gCathair na Gaillimhe os cionn €100 míle euro a bhailiú don Institiúid Taighde Ailse Brollaigh sa gcathair ag an deireadh seachtaine nuair a thug os cionn 200 fostaí de chuid an chomhlachta faoin dúshlán Peak 2 Peak Challenge.

What You'll Learn:Why the “Rule of Three” is a leadership game changerThe origin and impact of Atlas' TEDx talk: Start with WhoWhat pirate leadership teaches us about trust and motivationWhy success leaves clues—and how to collect themThe mindset shift from chasing opportunities to choosing legacy Leadership Gold:“Every leader I've admired kept it simple: People. Time. Money.” The Rule of 3.  Resources & Links:Download Atlas' "Best-Selling Book" ProcessWatch his TEDx Talk: Start with WhoConnect with Atlas on his podcast: TargetedAnd, follow him on LinkedIn for more great insights.  

Today, I'm talking with Brittany Honor—a dynamic leader with more than 12 years of experience spanning the medical device and consumer packaged goods industries. In this inspiring and practical conversation, Brittany and I dig into the realities of learning and development, change management, and field enablement—particularly in fast-paced and high-performing sales-driven organizations. Through candid stories, tactical strategies, and reflections on her own journey, Brittany equips L&D and talent professionals to navigate change, support teams, and elevate their careers with authenticity and impact.Subscribe to our weekly updates and monthly talent development newsletter here. Order Own Your Career Own Your Life on AmazonApply to Join us in the Talent Development Think Tank Community!This episode is sponsored by LearnIt, which is offering a FREE trial of their TeamPass membership for you and up to 20 team members of your team. Check it out here.Also iSpring Suite, an eLearning authoring tool that offers thousands of assets, quizes, and role play simulations. They are offering our listeners a free trial here. Connect with Andy here: Website | LinkedInConnect with Brittany Honor here: LinkedInIn this episode, Brittany shares:How she “fell into” L&D, moving from sales and leadership roles into developing future leaders.Why promoting top sales performers into management isn't always the answer—and the value of focusing on transferable leadership skills.The critical mindset shift from “super salesperson” to effective leader.Communication pitfalls in change management and why messaging must start with the most impacted groups.The importance of listening and needs assessments for successful technology and training rollouts.How to handle requests for training—often uncovering root causes like trust, not just surface skills.Why authenticity, vulnerability, and ownership are essential for leaders.The role of clarifying personal values in driving career satisfaction and growth.Practical ways to build your personal brand alongside a corporate L&D career.How networking (especially on social media) can open doors and boost your professional impact.Thanks for listening! Be sure to subscribe and share with your colleagues and friends.

Este año la ONU cumple 80 años, y sin ella el mundo no sería igual. En épocas de guerra es urgente defender la palabra, es lo único que nos salva. En la guerra nadie habla: las acciones violentas predominan. A través de este podcast te invitamos a que te unas a la defensa del diálogo pacífico. Hacemos un breve recuento sobre los primeros pasos del derecho internacional y los derechos humanos, desde regulaciones tempranas como las de Aragón y Castilla en la defensa de los indios en el Imperio Español, pasando por principios universales de Emmanuel Kant, y llegando al crisol del pensamiento liberal en América, después de las independencias del siglo XIX. A partir de allí abordamos cómo se gestó la ONU, sus características, visiones y sus más importantes aportes durante el siglo XX. La ONU ayudó a descolonizar el mundo de pensamientos imperiales y todavía hoy lucha, a pesar de todo, por la seguridad, la libertad y la dignidad humana. Notas del episodio:   Este episodio fue traído a ustedes gracias a Boston Scientific  Si estás interesado en pensar los terribles acontecimientos del hoy, pero no quieres perder la esperanza en el intento, visita la columna de Rodrigo Uprimny: “”Un deber activo de esperanza?”, nuestro invitado especial para la realización de este podcast. Si quieres conocer más acerca del papel mundial de la ONU, desde su nacimiento hasta nuestros días, consulta los eventos oficiales destacados en la Historia de la ONU. Si quieres indagar más sobre el papel de Colombia en la ONU, te recomendamos dos textos: 1) “Colombia en la Asamblea General de las Naciones Unidas, 1946-2021 Construcción – Protagonistas – Discursos”, publicado por la Cancillería de Colombia, y 2) “Colombia en la ONU: 1945 - 1995” de Álvaro Tirado Mejía. Para comprender las complejidades que enfrenta la ONU desde sus dos grandes tensiones, “Idealismo vs. Realismo geopolítico” y “Universalismo vs. Reconocimiento de soberanías”, te invitamos a consultar el libro “Por una Constitución de la Tierra - La humanidad en la encrucijada” de Luigi Ferrajoli. Para conocer más sobre cómo funciona la crueldad de la guerra, te recomendamos revisar el libro “Calle Este-Oeste - Sobre los orígenes de “genocidio” y “crímenes contra la humanidad” de Phillipe Sands. No renunciemos a la esperanza.   Sigue mis proyectos en otros lugares:  YouTube ➔ youtube.com/@DianaUribefm  Instagram ➔ instagram.com/dianauribe.fm Facebook ➔ facebook.com/dianauribe.fm Sitio web ➔ dianauribe.fm Twitter ➔ x.com/DianaUribefm  LinkedIn ➔ www.linkedin.com/in/diana-uribe    Gracias de nuevo a nuestra comunidad de Patreon por apoyar la producción de este episodio. Si quieres unirte, visita www.dianauribe.fm/comunidad  

In this episode of Medsider Radio, we had a really engaging conversation with James (Jim) Corbett, CEO of AVITA Medical.AVITA Medical's RECELL system uses Spray-On Skin Cell technology to accelerate healing for patients with severe burns and wounds.  Jim brings nearly 40 years of medical device leadership experience to AVITA Medical. His career spans global commercial and operational roles, including President of Boston Scientific and General Manager of Scimed Life Systems. Jim has served as CEO of six companies, including three publicly traded entities — Microtherapeutics, ev3, and Alphatec Spine — as well as CathWorks, Home Diagnostics, and Vertos Medical.In this interview, Jim shares lessons from a career spanning global medtech leadership positions — including the importance of hands-on fundraising, adapting sales strategies as products mature, and how generating clinical evidence beyond FDA requirements serves commercial adoption.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Jim Corbett.

Botulinumtoxin, är världens giftigaste ämne som produceras ur bakterien Clostridium Botulinum. Hör Wojciech Duzynski, överläkare på neurologiska kliniken på universitetets sjukhuset i Malmö som i över 30 år använt Botulinumtoxin vid behandling av olika symtom hos patienter med Parkinsons sjukdom.Parkinsonpoddens annonsörer är Navamedic, AbbVie, Boston Scientific, Merz Therapeutics Nordics AB och CureMed Nordic AB. Företagen har ingen påverkan på programval eller innehåll.Programledare: Anders StålhammarTekniker/bollplank: Inge Amundsenhttp://www.parkinsonpodden.seanders@parkinsonpodden.sewww.alltomparkinson.se Hosted on Acast. See acast.com/privacy for more information.

In this episode of Medsider Radio, we sat down with Todd Usen, CEO of Adagio Medical.Adagio specializes in catheter-based ablation technologies for the treatment of cardiac arrhythmias, with a focus on ventricular tachycardia (VT).  Todd has over three decades of leadership experience in the medical technology industry, with particular expertise in commercial strategy, operational performance, and business transformation. Before joining Adagio, Todd served as CEO of Minerva Surgical, a women's health company, and as CEO of Activ Surgical, a digital surgery startup. Todd has also served in executive positions at Olympus, United States Orthopedics, Smith and Nephew, and Boston Scientific.In this interview, Todd shares insights on making usability central to commercialization strategy, leveraging breakthrough designation beyond regulatory validation, and assembling effective boards by carefully selecting both investor and independent members who bring operational expertise.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Todd Usen.

Join HRS Board Member Prashanthan Sanders, MBBS, PhD, FHRS (University of Adelaide) as he discusses this exciting paper, presented at Heart Rhythm 2025. He is joined in the Heart Rhythm Tv Studio in San Diego, California by Louise Segan, MBBS, MPH (Alfred Health), and Takanori Yamaguchi, MD, PhD (Saga University). This discussion took place on-site at Heart Rhythm 2025.   https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)01245-7/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): T. Yamaguchi: Honoraria/Speaking/Consulting: Abbott Japan, Biotronik, Boston Scientific, Abbott Medical, Japan Medtronic, Inc., Daiichi Sankyo, Novartis, Japan Lifeline, Nihon Kohden, Bayer Healthcare Pharmaceuticals Japan, Boehringer Ingelheim L. Segan: Nothing to disclose.

In this episode of the Latin Wealth Podcast, we dive into major developments shaping Latin America's economic and political landscape in 2025. From Costa Rica's quiet rise as a high-tech powerhouse to China's growing influence across Latin America — and the unexpected shift of Latin American migration from the U.S. to Spain — we break down what these global shifts mean for Latinos around the world.Segment 1: Costa Rica's Tech TransformationCosta Rica is becoming Latin America's high-tech hub, recording over $32 billion in exports in 2024. With investments from global tech giants like Intel and Boston Scientific, and a booming medical device sector, this Central American nation is showing the power of innovation, sustainability, and national branding. We discuss how this model could inspire other countries in the region.Segment 2: China's Visa-Free PlayChina is expanding visa-free travel to citizens of Brazil, Argentina, Chile, Peru, and Uruguay. This is more than a tourism policy — it's a strategic move to deepen China's presence in Latin America. We discuss what this means for global partnerships, trade routes, and diplomatic influence in the Western Hemisphere.Segment 3: “The American Dream is Over?”Trump's aggressive deportation policies are causing many Latin Americans to abandon the U.S. for Spain. We explore how political pressure, cultural ties, and economic opportunity are reshaping migration patterns, and what this means for Latinos chasing opportunity abroad.This episode covers:- Latin America's tech innovation and economic growth- China's bold diplomatic strategies in the region- How shifting immigration policies are changing the Latino diaspora- The future of the American Dream for Latin communities

Prashanthan Sanders, MBBS, PhD, FHRS, University of Adelaide is joined by Jenish Shroff, MBBS, MD, Australian National University, and Pugazhendhi Vijayaraman, MD, FHRS, Geisinger Heart Institute, to discuss this first-in-human feasibility study evaluated a novel helix-based leadless pacemaker (LPCSP) designed to achieve left bundle branch area pacing (LBBAP), a capability current LPs lack. The device was temporarily implanted via the internal jugular vein into the interventricular septum in 14 patients, with successful implantation in 10. Electrical performance metrics, including pacing threshold, R-wave amplitude, and impedance, were within acceptable clinical ranges. LBBAP capture was achieved in 5 patients, with no serious device-related adverse events in 85.7% of cases. The study supports the acute safety and feasibility of LPCSP for conduction system pacing.    https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)02378-1/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): P. Vijayaraman: Honoraria/Speaking/Consulting: Biotronik, Boston Scientific, Abbott Medical, Medtronic, Inc. Research (Contracted Grants for PIs and Named Investigators only): Medtronic Fellowship Support: Medtronic J. Shroff: Nothing to disclose.

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Johns Creek: Number One Best U.S. City to Live In, with Mayor John Bradberry and Brian Lynam, Boston Scientific (GNFCC 400 Insider, Episode 107) Join GNFCC CEO Kali Boatright in this episode of the GNFCC 400 Insider podcast as she chats with Johns Creek Mayor John Bradberry and Boston Scientific Senior Director Brian Lynam, discussing […] The post Johns Creek: Number One Best U.S. City to Live In, with Mayor John Bradberry and Brian Lynam, Boston Scientific appeared first on Business RadioX ®.

Michael S. Lloyd, MD, FHRS, Emory University is joined by Edward P. Gerstenfeld, MD, MS, FHRS, University of California, San Francisco, and Christopher C Cheung, MD, MPH, FHRS, Sunnybrook HSC, University of Toronto, to discuss the VOLT-AF IDE study evaluated the safety and effectiveness of a novel balloon-based pulsed field ablation (PFA) catheter system for treating paroxysmal and persistent atrial fibrillation (PAF and PsAF). Conducted at 34 global sites, the study enrolled 394 subjects, with 320 included in the primary analysis. Acute pulmonary vein isolation (PVI) success was achieved in over 99% of veins, and primary serious adverse events occurred in only 1.9% of patients, with no significant complications like esophageal injury or hemolysis. Procedure metrics showed efficient operation times, and early 6-month data suggest promising effectiveness. These initial findings support the Volt™ PFA system as a safe and effective treatment option for AF.    https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)02168-X/fulltext Host Disclosure(s): M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Arga Medtech, Circa Scientific Membership on Advisory Committees: Boston Scientific Contributor Disclosure(s):   E. Gerstenfeld: Honoraria/Speaking/Consulting: Medtronic, Boston Scientific, Biosense Webster, Abbott, Varian Medical Systems, Biotronik Other Non-Financial Relationships: Farapulse, Adagio Medical, Boston Scientific, Abbott Medical, Research (Contracted Grants for PIs and Named Investigators only): Abbott Medical Officer, Trustee, Director, Committee Chair, or Any Other Fiduciary Role: American College of Cardiology Foundation C. Cheung: Nothing to disclose.

Sandeep A Saha, MD, MS, FHRS, Oregon Heart Center PC is joined by Saket Sanghai, MD, FHRS, Oregon Health & Science University, and Naga Venkata Krishna Chand Pothineni, MD, Kansas City Heart Rhythm Institute, to discuss how the study evaluated the effectiveness of implantable loop recorders (ILRs) in detecting arrhythmias in patients with hypertrophic cardiomyopathy (HCM). Traditional monitoring methods, like Holter monitors, often miss intermittent arrhythmic events in HCM patients. ILRs, offering continuous long-term monitoring, were found to identify clinically significant arrhythmias that might otherwise go undetected. The findings suggest that ILRs can play a crucial role in risk stratification and management of HCM patients, potentially guiding decisions regarding interventions such as implantable cardioverter-defibrillator (ICD) implantation. Overall, ILRs enhance the detection of arrhythmias in HCM, leading to improved patient care.    https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/10.1016/j.jacep.2025.03.005 Host Disclosure(s): S. Saha: Honoraria/Speaking/Consulting Fee: Medtronic Membership on Advisory Committees: Medtronic Inc. Contributor Disclosure(s): S. Sanghai: Research: Siemens Healthcare Stocks (Publicly Traded): Apple Inc., Alphabet Inc., Amazon Stock Options (Publicly Traded): Intel K. Pothineni: Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biosense Webster, Inc., Boston Scientific

In this episode of the Next Level Healing Podcast, Dr. Tara Perry interviews John K. Bates, Founder of Executive Speaking Success. John has trained and coached leaders at NASA—including the astronauts—GE Aerospace, US Navy Special Operations, Johnson & Johnson's JLABS, Boston Scientific, Google, Intuit, and many more. His programs consistently earn Net Promoter Scores of 92+, and his clients don't just thank him—they recommend him as the best leadership communication coach working today.Work with Dr. Tara PerryTune in every week for a new episode of Next Level Healing. Subscribe on your favorite podcasting platform and never miss an episode!

Mais de 10 milhões de pessoas no mundo são afetadas pelo mal de Parkinson, e esse número pode dobrar até 2050. Não há, ainda, cura, mas as terapias de estimulação cerebral profunda, conhecidas como DBS, combinam dispositivos digitais com implantes cerebrais para mudar a vida de quem sofre com doenças neurodegenerativas. Como funcionam esses marca-passos cerebrais e como a IA os torna ainda mais precisos? Conversamos com o diretor de neuromodulação da Boston Scientific no Brasil, Lucas Silva, para entender essa história, cheia de finais felizes.Links do episódioA página do LinkedIn de Lucas SilvaO site Viver com ParkinsonO documentário "Still - ainda sou Michael J. Fox", na Apple TV+A série "Shrink - Falando a Real", na Apple TV+O livro "The Ageless Brain: How to Sharpen and Protect Your Mind for a Lifetime", de Dale BredesenO livro "Uma viagem pelo cérebro. A via rápida para entender neurociência", de Carla Tieppo A The Shift é uma plataforma de conteúdo que descomplica os contextos da inovação disruptiva e da economia digital.Visite o site www.theshift.info e assine a newsletter

They're good dogs, especially when Kasey Labelle joins us to share her lifelong connection with puppies. She recounts her childhood with two family dogs before introducing Rhino, her beloved blue nose pitbull who chose her when he was just three weeks old and remained her companion for nearly 15 years. Kasey discusses how she's coped with Rhino's passing by becoming a dog walker, speaks passionately about the misconceptions surrounding pitbulls, and shares how Rhino's loving personality challenged those stereotypes. She also offers thoughtful advice for potential dog owners, emphasizing the importance of viewing dogs as family members and the different factors to consider when choosing the right dog.Guest BioKasey Labelle, CPWA (she/her) is a UX and design engineering leader with a passion for design systems and accessibility. In her current role as a Design Architect at iSeatz, she's leading the evolution of a design system that powers a white-label travel loyalty platform. Previously, she built and led the multi-disciplinary design system team and accessibility program at Boston Scientific, establishing 0-1 and 1-n strategies and serving as a player-coach. In her downtime, you can find her at the beach, an art museum, concert, or game night; walking dogs; obsessing over spreadsheets; traveling; or attending fine arts and crafts workshops with friends.LinksKasey's website: kaseyllabelle.comKasey on LinkedIn: linkedin.com/in/kaseyllabelleCreditsCover design by Raquel Breternitz.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Join host Prashanthan Sanders, MBBS, PhD, FHRS, and episode guests Jason G. Andrade, MD, FHRS, and Melanie Gunawardene, MD, as they discuss Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation. This discussion was recorded in person at EHRA 2025 in Vienna, Austria. The article under discussion was presented at EHRA 2025 and simultaneously published in the New England Journal of Medicine.   https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2502280   Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical; Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical   Contributor Disclosure(s): M. Gunawrdene: Honoraria/Speaking/Consulting: Farapulse, Abbott Medical, Boston Scientific, Medtronic, Biotronik, Luma Vision, Bristol Myers Squibb J. Andrade: Honoraria/Speaking/Consulting: Boston Scientific, Medtronic, Inc., Biosense Webster, Inc.

Alissa Coram and Justin Nielsen analyze Monday's market action and discuss key stocks to watch on Stock Market Today.

In this episode, a multidisciplinary panel of PE key opinion leaders share insights and challenge perceived myths within the landscape of PE real world evidence and care. Listen in for the latest data, contemporary treatment strategies, and preview anticipated future developments in this rapidly evolving field of PE.

In this episode, the Surgical Endoscopy team, accompanied by Chief Medical Officer Dr. Brian Dunkin of Boston Scientific, review primary and revisional endoscopic treatment options for bariatric patients. They focus on the emerging data available for procedures such as endoscopic sleeve gastroplasty (ESG) and endoscopic gastrojejunal revision (EGJR) and offer technical tips on how to perform the procedures. In addition, they discuss accessibility challenges for patients and provide insight into the future direction of bariatric endoscopy as a field.  Hosts: ·      Dr. Sullivan “Sully” Ayuso, Minimally Invasive Surgery, Endeavor Health (Evanston, IL), @SAyusoMD (Twitter) ·      Dr. Trevor Crafts, Minimally Invasive Surgeon, Rocky Mountain VA Medical Center (Denver, CO), @CraftsTrevor (Twitter)  ·      Dr. H. Masson Hedberg, Minimally Invasive Surgeon, Endeavor Health (Evanston, IL) ·      Dr. Michael Ujiki, Professor and Louis Biegler Chair of Surgery, Endeavor Health (Evanston, IL), @UjikiMike ·      Dr. Brian Dunkin, Chief Medical Officer at Boston Scientific, @briandunkinmd Learning Objectives:  -       Identify and Describe Common Endobariatric Procedures: Learners will be able to name and briefly describe at least three common endobariatric procedures discussed in the episode, including Endoscopic Sleeve Gastroplasty (ESG), Endoscopic GJ Revisions (Transoral Outlet Reduction - TORR/EGJR), and Intragastric Balloons, along with their historical context and evolution. -       Explain the Mechanism and Benefits of Endoscopic Sleeve Gastroplasty (ESG): Learners will be able to articulate the procedural technique of ESG, including the U-shaped suture pattern, its impact on gastric volume reduction, and the proposed mechanisms of weight loss, such as slowed gastric emptying and hormonal changes, as compared to laparoscopic sleeve gastrectomy. -       Discuss the Role of Technology and Training in Endobariatrics: Learners will be able to explain the significance of endoscopic suturing devices like the Overstitch in the advancement of endobariatric procedures and recognize the importance of specialized training, including the recommendations against fundal suturing for safety during the initial learning curve. -       Compare and Contrast Endobariatric Procedures with Surgical and Pharmacological Obesity Treatments: Learners will be able to discuss the position of endobariatric procedures as a "gap therapy" in the spectrum of obesity treatments, highlighting their benefits such as reduced invasiveness, lower complication rates, faster recovery, and increased patient access compared to surgery, as well as their potential role in conjunction with pharmacologic therapies like GLP-1 agonists. -       Recognize Key Considerations and Potential Complications of Endobariatric Procedures: Learners will be able to identify important technical considerations during ESG, such as achieving full-thickness bites while avoiding injury to adjacent organs, and describe common post-procedure issues associated with intragastric balloons, including nausea, vomiting, and the need for general anesthesia during removal. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity: https://pubmed.ncbi.nlm.nih.gov/39888616/ Surgical Endoscopy Series Ep. 1: An Introduction to Surgical Endoscopy: https://app.behindtheknife.org/podcast/surgical-endoscopy-series-ep-1-an-introduction-to-surgical-endoscopy Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Alissa Coram and Ken Shreve analyze Wednesday's market action and discuss key stocks to watch on Stock Market Today.

In this episode of Medsider Radio, we sat down with Randy Pritchard and Erica Rogers, leaders of Axena Health. Axena is transforming pelvic floor therapy with Leva, a device bringing clinically-proven, supervised pelvic floor muscle training into women's homes. Randy, CEO of Axena, brings nearly 25 years of healthcare experience to the company, most recently as CEO of Pillar Biosciences and previously holding leadership positions at Roche Diagnostics, where he spent 18 years developing commercial expertise. Erica, who sits on Axena's Board of Directors, spent a decade as President and CEO of Silk Road Medical, leading the company from early clinical trials through IPO and eventual acquisition by Boston Scientific. A returning guest to the podcast after nearly half a decade, Erica previously held roles at Medicine360, co-founded two other medical device companies, and spent over 12 years at Boston Scientific prior to her role at Silk Road.In this interview, they share essential medtech commercialization insights: identify your specific patient segment, build continuous clinical evidence, and communicate consistently with investors. Their experience offers invaluable lessons for medical device entrepreneurs navigating today's complex healthcare landscape.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Randy Pritchard and Erica Rogers.

Jacob Raymer is an internationally recognized speaker who addresses corporate, public and universityaudiences on the subjects of leadership roles and responsibilities, cultural transformation, and how to achieveorganizational excellence with the right behavior and sustainable long-term results. As the Shingo Institute'sformer Director of Education, Jacob co-created the Shingo Model and developed the foundational learningcourses taught at the Shingo Institute. He has trained Shingo examiners and thousands of individualsworldwide on how to assess and establish lean mindsets and method. In 2006, Jacob pioneered the concept ‘key behavior indicators' (KBIs). Today many world-wide organizations have now adopted this term and concept to expand their desired outcomes with key performance indicators(KPIs). By combining KPI and KBI, Jacob's consulting firm has led the development and application of behavior-based strategy deployment; building systems to drive the right behavior; and developing internal behavioralassessments. The United State Airforce invited Jacob to join a team of global subject matter experts to create their leanleadership development program (AFSO21) in 2006. He was commissioned to lead the leadershipdevelopment for United States Airforce Europe – working with leaders throughout 93 countries. His workchallenged leaders' mindsets around lean tools and how to lead by integrating guiding principles.After spending over a decade with the Shingo Institute he joined Munson Healthcare, northern Michigan'slargest healthcare system as their Chief Transformation Officer. At Munson Healthcare, Jacob spent sevenyears creating and deploying an organizational lean operating system and alignment framework anchored toguiding principles that are now integrated into nine hospitals and over 150 clinics. Currently Jacob supports the Shingo Institute as a Faculty Fellow by continuing his work in creating learning frameworks to help organizations effectively integrate the Shingo Model. He was recognized and awarded as alifetime member to the Shingo Academy in 2021 for his global contributions to operational excellence. Jacob continues to support various organizations through executive coaching and consulting. Current companies include: Amazon, General Motors, Android, UCLA Healthcare System, University of KansasHealthcare System and University of New Mexico Healthcare System Past organizations include: 3M, Raytheon Missile Systems, Boston Scientific, Boeing, Daimler, Intermountain Healthcare, Perrigo, Canadian Government-EDC, Switzerland Government-HealthcareLink to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

Join host and Digital Education Chair Prashanthan Sanders, MBBS, PhD, FHRS, as he discusses this article from Nature with guests Anand N Ganesan, MBBS, PhD, and Tina Baykaner, MD, MPH. This trial was also presented as a late-breaking clinical trial at Heart Rhythm 2024.   https://www.hrsonline.org/education/TheLead https://www.nature.com/articles/s41591-025-03517-w   Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical; Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): A. Ganesan: Honoraria/Speaking/Consulting: Biosense Webster, Inc. T. Baykaner: Honoraria/Speaking/Consulting: Medtronic, Pacemate, Volta Medical, iRhythm Technologies; Research: NIH   This episode is worth 0.25 ACE credits. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode99

This episode covers: Cardiology This Week: A concise summary of recent studies Current indications for pulmonary vein isolation Conduction system pacing EHRA 2025 scientific highlights Host: Susanna Price Guests: Haran Burri, Isabel Deisenhofer, Helmut Puererfellner, Emma Svennberg Want to watch that episode? Go to: https://esc365.escardio.org/event/1803   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Helmut Puererfellner has declared to have potential conflicts of interest to report: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities for the following companies: Abbott, Biotronik, Biosense Webster, Boston Scientific, Daiichi Sankyo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week, we step In The Lobby with Brenda Becker, Senior Vice President of Global Government Affairs at Boston Scientific. With a career that spans state government, the private sector and the White House, Brenda brings a wealth of experience—and a heart rooted in Midwest values.In this conversation, Brenda reflects on the power of mentorship, something she's keenly known for across this town and the entire advocacy community. Whether it's guiding young professionals or offering seasoned advice to peers, her thoughtful, inclusive approach is a hallmark of her leadership.Brenda's story is a masterclass in public affairs—and in paying it forward. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit thefridayreporter.substack.com

Michael S. Lloyd, MD, FHRS, Emory University, is joined by Harish Doppalapudi, MD, FHRS, University of Alabama at Birmingham, to discuss this provocative article from late 2024 on Pulmonary Vein Isolation versus SHAM Intervention in Symptomatic Atrial Fibrillation. Special thanks to Prashant D. Bhave, MD, FHRS for his contributions to the discussion. https://www.hrsonline.org/education/TheLead https://jamanetwork.com/journals/jama/fullarticle/2823283#google_vignette Host Disclosure(s): M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Membership on Advisory Committees: Boston Scientific Contributor Disclosure(s): H. Doppalapudi: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Fellowship Support: Medtronic, Inc., Biosense Webster, Inc., Boston Scientific, Abbott Medical, Biotronik   This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode97

Want to thrive in medical sales? In this episode, TJ, a regional business director specializing in cardiology, shares insider strategies for success—from fostering a growth mindset to mastering self-leadership. Learn how top performers refine their processes, understand their motivations, and leverage innovation to drive sales in coronary artery disease and structural heart technologies.   Discover why psychology beats tactical selling when building strong healthcare partnerships and how relationship-building is the key to long-term success. TJ also reveals how Boston Scientific onboards new reps to ensure they make an impact from day one, engaging effectively with hospital accounts.   Thinking about breaking into medical sales from a different industry? We explore how a restaurant server can successfully pivot into medical sales, the importance of demonstrating growth, and what hiring managers look for in standout candidates. Plus, get expert tips on acing interviews, crafting personalized follow-ups, and making authentic connections that lead to opportunities.   Whether you're a seasoned rep, an aspiring medical sales professional, or a leader looking to build a high-performing team, this episode is packed with real-world insights, career strategies, and actionable advice to help you succeed in the dynamic world of medical sales.   Meet the guest: TJ Jones is a Regional Sales Director for Boston Scientific, a global company that transforms lives through innovative medical solutions. He is passionate about positively impacting patient care and helping sales professionals reach new milestones professionally and personally. Connect with TJ: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!  

Do you ever wish you could be a fly on the wall at a tumor board meeting? In this episode of BackTable, we're excited to give you an insider's view of the real case discussions that take place during hepatocellular carcinoma (HCC) tumor boards. Host Dr. Zach Berman sits down with a multidisciplinary team, including Drs. Adam Burgoyne (medical oncologist), Heather Patton (hepatologist), Siddharth Padia (interventional radiologist), and Gabriel Schnickel (transplant and hepatobiliary surgeon). Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125743 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The team walks through a range of diverse HCC cases, reviewing patient histories, imaging, and treatment options. They cover eight cases in total, each featuring patients with varying treatment histories, comorbidities, liver function, and lesion characteristics. For the full educational experience, we recommend watching the video format on our YouTube channel. --- TIMESTAMPS 00:00 - Introduction 00:47 - Case 1: Small Lesion in a Young Patient 05:01 - Case 2: Moderate Sized Lesion in an Older Patient 11:10 - Case 3: Multifocal HCC with Dominant Lesion 21:09 - Case 4: Dominant Lesion with Portal Hypertension 32:08 - Case 5: Ruptured Solitary Lesion 34:34 - Case 6: Rupture with Multifocal Lesions 44:08 - Case 7: Portal Vein Invasion 52:12 - Case 8: Metastatic HCC After Transplant --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Are you seeking to build your reputation and patient base within interventional oncology? In this episode, host Dr. Zachary Berman interviews Dr. Siddarth Padia, Dr. Tyler Sandow, Dr. Kavi Krishnasamy, and Dr. Kevin Burns about their journeys into interventional oncology (IO) and their experiences providing care in different practice settings. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125742 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The doctors begin by discussing how they became interested in interventional oncology, with most of them recognizing opportunities to address unmet needs in the field. Each guest shares insights on the timelines and challenges involved in starting their IO practices, which vary significantly today. For instance, telehealth clinics are particularly viable in private practice IO, thanks to conferencing software and virtual translators. Hybrid care models, which combine in-person and remote consultations, can help overcome patient-level barriers such as time and transportation. The panel also emphasizes how increased clinic availability can significantly drive growth in procedural volume. Finally, they offer advice for starting an IO practice, including the importance of having clinic support staff, building strong relationships with referring physicians, and staying up to date with new technologies. --- TIMESTAMPS 00:00 - Introduction 05:38 - Balancing Career Interests and Expectations 07:10 - Building an Interventional Oncology Practice 13:42 - Gaining Trust from Referring Physicians 17:33 - Importance of Open Communication 19:19 - Comparing Clinic Settings 26:01 - Essential Components of a Clinic 33:28 - Narrowing Your Interventional Practice 40:09 - Introducing New Technology --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Boston Scientific is looking at workforce planning in an entirely new way. We got the rare chance to hear all about it from Brenda Kowske, their Senior Director of Talent Analytics and Workforce Planning.With 50,000 employees worldwide and a rapidly growing footprint, they're navigating big challenges with fresh approaches.We talked with Brenda about how her team is breaking down traditional HR silos, integrating workforce planning into business decisions, and staying ahead of the curve with AI and skills-based planning.She's been in this space for over a decade and brings a sharp perspective on what works—and what doesn't.From creating global talent pods to using unexpected data like happiness indexes, Brenda walked us through how Boston Scientific is balancing data, technology, and strategy to make workforce planning a true competitive advantage.You will want to hear this episode if you are interested in...Intro [0:00]How AI is changing jobs, skills, and how teams are truly built [1:44]Using location and happiness data to make better workforce choices [2:29]The challenge of moving from job-based to skill-based planning [7:00]How to keep workforce data private while still using it smartly [21:00]Why Boston Scientific keeps workforce planning “always on” [24:30]How AI could make it easier to help employees grow their skills [33:20]Resources & People MentionedGDPR – General Data Protection Regulation OverviewCorporate Social Responsibility Directive (CSRD) – CSRD Information (European Commission)Anaplan – Anaplan Official WebsiteConnect with Brenda KowskeBrenda Kowske on LinkedInConnect With Red Thread ResearchWebsite: Red Thread ResearchOn LinkedInOn FacebookOn TwitterSubscribe to WORKPLACE STORIES

Top Stories:1. Starbucks to lay off 1,100 corporate employeesSeattle Times article2. Seattle tech company adds to C-suitePSBJ article3. Sounders will give away tickets to first timersSeattle Times article or Sounders Press Release4. Pickleball chain coming to FremontSeattle Magazine article or PBSJ articleAbout guest co-hosts Lindsay Droz and Kristi Lord - Co-founders, L'AVANT:L'AVANT sells bougie, eco-friendly cleaning products with plant based ingredients like hand soap, dish soap, laundry detergent, multipurpose spray and more. Lindsay and Kristi started this company about 5 years ago. Lindsay has a sales and marketing background and worked in the medical device world, specifically for Boston Scientific for 15 years. Kristi worked in finance and investments and was the COO of an Asset Management company prior to L'AVANT.About host Rachel Horgan:Rachel is an independent event producer, emcee and entrepreneur. She worked for the Business Journal for 5 years as their Director of Events interviewing business leaders on stage before launching the weekly podcast. She earned her communication degree from the University of San Diego. Contact:Email: info@theweeklyseattle.comInstagram: @theweeklyseattleWebsite: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.theweeklyseattle.com⁠⁠

Is surgery truly the "cure" for hepatocellular carcinoma (HCC), and when is it a viable option? In this episode, Dr. Sabeen Dhand leads a roundtable discussion with interventional radiologist Dr. Siddharth Padia and transplant/hepatobiliary surgeons Dr. John Seal and Dr. Gabriel Schnickel, delving into the complexities of surgical treatments for HCC and the evolving landscape of liver resection and transplantation. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125741 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The doctors begin by discussing how they manage patient expectations regarding both palliative and curative treatments, highlighting the risk of recurrent HCC as a new lesion. They then outline key factors that influence their recommendations for liver transplant versus resection, such as the extent of underlying liver disease, the function of the future liver remnant, body habitus, overall health, and organ availability. The surgeons also review various surgical approaches to liver resection and recent advancements in liver transplantation, including living donor transplants and the ability to refer patients for downstaging procedures. Dr. Padia explains the original role of Y90 as a bridging treatment to downstage tumors and promote hypertrophy in the non-diseased liver segments, preparing the organ for surgical resection. However, Y90 treatment can also lead to the formation of adhesions, which may complicate future surgeries. Finally, the doctors discuss strategies to improve care coordination between community physicians and transplant centers to optimize patient outcomes. --- TIMESTAMPS 00:00 - Curative vs. Palliative Treatment 04:03 - Choosing Between Transplantation and Resection 05:47 - Liver Resection Types 07:27 - Bridging Role of Y90 12:14 - Evolving Landscape of Liver Transplantation 20:59 - Patient Counseling in Minimally Invasive Procedures 28:40 - Considerations for Surgery After Y90 33:32 - Coordination Between Specialists 40:08 - Immunotherapy as a Bridge to Transplant --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

In this episode of the DeviceTalks Weekly Podcast, it's a DeviceTalks Team Up. Editorial Director Tom Salemi and Managing Editor Kayleen Brown interview Doug Evans, CEO and President of Lungpacer Medical. Evans shares the tragic reason he vowed to start a company that would help wean patients off ventilators. We'll hear his success story in the podcast, but join us at DeviceTalks Boston to hear the story behind the AeroPace technologies as Evans will be joined by Lungpacer COO Viral Thakkar and Mike Longo, vice president of product development. Register to attend DeviceTalks Boston at Boston.DeviceTalks.com. If you missed our early bird rate use the code mentioned in the podcast on March 1 and 2. Before the DeepDive conversation, we'll have Mass Device Honcho Chris Newmarker's Newsmakers - Medtronic, Solventum, FDA layoffs, Boston Scientific, and Teleflex. Jim Hammerand, managing editor of Medical Design & Outsourcing, opens with an overview of the magazine's current Min-Vasive issue. You can find all the articles mentioned at medicaldesignandoutsourcing.com. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

The process of liver transplantation involves many complexities, and each patient's path to transplant is unique. To offer insider perspectives on this process, Dr. Zachary Berman sits down with transplant and hepatobiliary surgeon Dr. John Seal, as well as transplant hepatologists Dr. Heather Patton and Dr. Steve Young. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125740 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The panel begins by discussing the multidisciplinary pre-transplant evaluation process, which assesses factors such as liver function, comorbidities, surgical risk, and the availability of psychosocial support. Once a patient is listed for transplant, they enter a system that prioritizes those with the highest Model for End-Stage Liver Disease (MELD) score. During the waiting period, several comorbidities should be carefully monitored. Dr. Seal explores the impact of portal vein hypertension and portal vein thrombosis, explaining how these conditions may necessitate intraoperative thrombectomy or bypass. Dr. Patton and Dr. Young focus on considerations for using anticoagulation in patients with a high baseline bleeding risk and selecting the appropriate anticoagulant for patients listed for transplant. For patients with hepatocellular carcinoma (HCC), eligibility for MELD exception points may depend on factors such as time spent on the waiting list, adherence to the Milan criteria, and the presence of extrahepatic complications of liver disease. The panel also discusses bridging therapies to transplant, including Y90 and TACE. In the peri-transplant phase, they highlight innovations such as living donor transplants, liver perfusion pumps, and the use of hepatitis C- and HIV-positive organs. Finally, the discussion turns to post-transplant considerations, including surgical complications, organ rejection, immunosuppression, predictors of HCC recurrence, and long-term surveillance. --- TIMESTAMPS 00:00 - Introduction 01:16 - Current Landscape of Liver Transplantation 03:22 - Transplant Evaluation Process 09:48 - Timeline from Listing to Transplantion 11:16 - Treating Portal Vein Thrombosis and Hypertension 18:44 - MELD Exception Points 22:05 - Bridging Therapies 25:34 - Peri-Transplant Considerations 30:53 - Post-Transplant Period 37:39 - Repeat Transplantation --- RESOURCES Model for end-stage liver disease (MELD) and allocation of donor livers (Wiesner et al, 2003): https://www.gastrojournal.org/article/S0016-5085%2803%2950022-1/fulltext Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis- Milan Criteria (Mazzaferro et al, 1996): https://pubmed.ncbi.nlm.nih.gov/8594428/ Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database (Mehta et al, 2019): https://pmc.ncbi.nlm.nih.gov/articles/PMC6445634/ CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Treatment of hepatocellular carcinoma (HCC), like that of many other cancers, spans a spectrum from curative to palliative intent. To explore the "grey zone" of treatment goals for intermediate-stage HCC patients, Dr. Sabeen Dhand interviews a panel of experts in the field: medical oncologists Dr. Adam Burgoyne and Dr. Lingling Du, along with interventional radiologists Dr. Kirema Garcia-Reyes and Dr. Zachary Berman. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125739 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The discussion begins with an explanation of the Barcelona-Clinic Liver Cancer (BCLC) staging system. While this system takes into account helpful factors such as liver function, performance status, and tumor burden, it fails to fully capture the true heterogeneity of the HCC patient population. Additional considerations include tumor biology, response to previous treatments, and the location of metastases. The specialists then share their experiences in treating patients with comorbid gastrointestinal cancers and mixed tumors, discuss the benefits of an interventional oncology clinic setting, and highlight virtual opportunities for connecting with tumor boards. They also offer advice on patient education regarding treatment options. --- TIMESTAMPS 00:00 - Introduction to BCLC Staging 03:02 - Impact of Performance Status 06:29 - Predictors of Survival in HCC 09:51 - Palliative versus Curative Treatment Intent 13:55 - Comorbid and Mixed Gastrointestinal Cancers 16:51 - Adverse Effects of Treatment 20:37 - Interventional Oncology in the Clinic Setting 23:06 - Navigating Multiple Provider Viewpoints 28:01 - Complex Case Examples --- RESOURCES BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update (Reig et al, 2022): https://www.journal-of-hepatology.eu/article/S0168-8278(21)02223-6/fulltext CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf